---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-001252"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T04:15:25.043589+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioLife Solutions Q4 preliminary revenue $22.7M, +31% YoY; cell processing beats FY guidance

## Summary
- Q4 2024 continuing ops revenue $22.7M (+31% YoY); cell processing $20.3M (+37% YoY, +7% sequentially).
- FY2024 continuing ops revenue $82.3M (+8% YoY); cell processing $73.5M exceeded raised guidance of $72-73M.
- Evo and Thaw platform revenue fell 14% YoY to $8.7M for FY2024; Q4 down 8%.
- Company completed divestitures of freezer and biostorage businesses, sharpening focus on CGT market.
- CEO cites momentum, fortified balance sheet; full 2024 results and 2025 outlook due in February earnings call.

## SEC filing metadata
- accession: 0001628280-25-001252
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828025001252/0001628280-25-001252-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828025001252/blfs-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-001252
- JSON: https://secwatch.observer/filing/0001628280-25-001252.json
- Plain text: https://secwatch.observer/filing/0001628280-25-001252.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.